German CMO Warned for Poor cGMP Training, Employee ‘Performance Lapses’

January 18, 2013
Improper staff training at Hameln Pharmaceuticals’ new state-of-the-art, sterile plant in Hameln, Germany, has given rise to employee “performance lapses,” a recently posted warning letter states. These lapses caused “significant violations” of good manufacturing practice regulations, it adds.
Drug Industry Daily